Evidence map›Paper›PMID 41685330›Full record

ArticleFrontiers in immunology2026

Leveraging cfDNA fragmentomic features for the early detection of colorectal cancer.

Lina Shan, Dengyong Xu, Jie Chen, Wenjia Liu, Ji Lin, Juhang Bao, Jianfei Huang, Hanqing Zhang, Hanchen Zhao, Wei Xue and 2 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Lina Shan *Department of Colorectal Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Dengyong Xu *Department of Colorectal Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Jie ChenDepartment of Operating Room, Shangyu Hospital of Traditional Chinese Medicine, Shaoxing, China.
Wenjia LiuOmixScience Laboratory, OmixScience Co., Ltd, Hangzhou, China.
Ji LinDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Juhang BaoDepartment of Colorectal Surgery, The First Affiliated Hospital of Ningbo University, Ningbo, China.
Jianfei HuangDepartment of Colorectal Surgery, Shaoxing People's Hospital, Shaoxing, China.
Hanqing ZhangUniversity of California, Davis, Davis, CA, United States.
Hanchen ZhaoOmixScience Laboratory, OmixScience Co., Ltd, Hangzhou, China.
Wei XueOmixScience Laboratory, OmixScience Co., Ltd, Hangzhou, China.
Ziao Lin *OmixScience Laboratory, OmixScience Co., Ltd, Hangzhou, China.
Bingjun Bai *Department of Colorectal Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Early detection of colorectal cancer (CRC) is crucial for improving patient outcomes. Cell-free DNA (cfDNA) analysis has emerged as a promising non-invasive approach for cancer detection. This study aims to develop a machine learning algorithm leveraging cfDNA fragmentomic features to accurately detect CRC. Methods: 573 individuals from Sir Run Run Shaw Hospital, two community healthcare centers and three additional medical centers, were collected between April 1, 2023, and December 12, 2025. Participants were divided into training, internal validation, and external validation cohorts. A variety of cfDNA fragmentomic features were analyzed and incorporated into machine learning models. The models were evaluated using 10-fold cross-validation and assessed for accuracy, sensitivity, specificity, and AUC values. We also performed differential analysis of key genomic features, such as Results: The machine learning algorithm demonstrated robust discriminative performance across all datasets using generalized linear modeling (GLM), achieving AUC values of 0.959 (training set), 0.979 (internal validation cohort), and 0.959 (external validation cohort). Notably, the model exhibited particularly strong classification accuracy for advanced-stage colorectal cancer (CRC). Comparative cfDNA profiling revealed distinct molecular signatures between benign and malignant samples: benign samples were characterized by elevated frequencies of Conclusion: This study demonstrates that cfDNA fragmentomic profiling, particularly differential patterns of

Indexed as

Biomarkers, TumorCell-Free Nucleic AcidsCirculating Tumor DNAColorectal NeoplasmsEarly Detection of CancerAgedAlu ElementsFemaleHumansMachine LearningMaleMiddle AgedBiomarkers, TumorCell-Free Nucleic AcidsCirculating Tumor DNAAlu elementscell-free DNAcolorectal cancerearly detectionmachine learning

Identifiers

PMID41685330
PMCPMC12891135

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.